

Amendments to the Claims

Please amend the pending claims with the following amended claims.

1-4. (Canceled)

5. (Currently amended) A method for predicting a phospholipidosis induction potential of a test compound, which comprises

- (1) determining the standard for the judgment of the presence or absence of a phospholipidosis induction potential of the test compound, which comprises:
 - (a) detecting expression variation of a set of genes set forth as SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23, in samples containing a mammalian cell exposed to each of two or more known phospholipidosis-inducing compounds and two or more known phospholipidosis non-inducing compounds, and
 - (b) using, as a standard value, an average variation rate capable of correctly judging the presence or absence of a phospholipidosis induction potential of the above-mentioned compounds by not less than about 70% based on the relationship between an average expression variation rate of the genes and the phospholipidosis induction potential; and
- (2) predicting a phospholipidosis induction potential of the test compound, which comprises:
 - (a) detecting expression variation of a set of ~~one or more~~ genes set forth as SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23 showing expression variation in correlation with phospholipidosis expression, in a sample containing ~~the~~ a mammalian cell exposed to the test compound or a sample taken from a mammal administered with the compound, and
 - (b) comparing the average variation rate of gene expression with the standard value obtained by the step (1).

6-8. (Canceled)

9. (Currently amended) The method of claim 57, wherein the step (1) further comprises examining validity of the standard value using other known phospholipidosis inducing compound and known phospholipidosis non-inducing compound.

10-11. (Canceled)

12. (New) The method of claim 5, wherein the phospholipidosis-inducing compound produces a myelin-like structure in the mammal cell.

13. (New) The method of claim 12, wherein the phospholipidosis-inducing compound is selected from the group consisting of amitriptyline, chlorcyclizine, fluoxetine, amiodarone, AY-9944, chlorpromazine, imipramine, tamoxifen, perhexiline, clozapine, sertraline, clomipramine, thioridazine, zimelidine, ketoconazole, loratadine and pentamidine.

14. (New) The method of claim 5, wherein the known phospholipidosis non-inducing compound is selected from the group consisting of acetaminophen, clarithromycin, disopyramide, erythromycin, flecainide, haloperidol, levofloxacin, ofloxacin, procainamide, quinidine, sotalol, sulfamethoxazole and sumatriptan.

15. (New) The method of claim 5, wherein the average variation rate is following formula:

$$\text{Average variation rate} = m_1 X_1 + m_2 X_2 + \dots + m_n X_n$$

wherein X is an expression variation rate of each gene, n is the total number of genes, $m_1 + m_2 + \dots + m_n = 1$ and $m_i = 1/n$.

16. (New) The method of claim 5, wherein the phospholipidosis is induced in an organ or tissue derived from the mammalian cell to be exposed to the compound.